New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT06126666

Recruiting now Disease control Sponsor: ABL Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called ABL103 in people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The study will enroll 96 participants to evaluate safety, dosing, and any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABL103 (a bispecific antibody that targets two proteins on cancer cells to boost immune response)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 96 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Seoul National University Bundang Hospital
RECRUITING

Seongnam, Seoul, 13620, South Korea
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, Seoul, 03080, South Korea
Sevrance Hospital
RECRUITING

Seoul, South Korea, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.